Pharma Mar, S.A. (OTCMKTS:PHMMF – Get Free Report) hit a new 52-week high on Wednesday . The company traded as high as $75.00 and last traded at $75.00, with a volume of 0 shares changing hands. The stock had previously closed at $75.00.
Wall Street Analysts Forecast Growth
Separately, Chardan Capital raised Pharma Mar to a “strong-buy” rating in a research note on Thursday, August 1st.
Check Out Our Latest Report on PHMMF
Pharma Mar Stock Performance
About Pharma Mar
Pharma Mar, SA, a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments.
Recommended Stories
- Five stocks we like better than Pharma Mar
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- How to Effectively Use the MarketBeat Ratings Screener
- 3 Penny Stocks Ready to Break Out in 2025
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.